The horrible convoluted statistical procedures that are used to make decisions about something as important as Alzheimer’s treatments

Richard Juster points to this article, “Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.” The article begins: On November 6, 2020, a US Food and Drug Administration (FDA) advisory committee reviewed issues related to the efficacy and safety of aducanumab, a human IgG1 anti-Aβ monoclonal antibody specific …